Otiprio

• OTIPRIO is for intratympanic or otic administration by a healthcare professional only.
• OTIPRIO is intended for single-patient use, discard unused portion.
• For bilateral otitis media with effusion, administer OTIPRIO as a single intratympanic administration of one 0.1 mL (6 mg) dose into each affected ear of pediatric patients (6 months of age and older), following suctioning of middle ear effusion.
• For acute otitis externa, administer OTIPRIO as a single 0.2 mL (12 mg) administration to the external ear canal of each affected ear of patients aged 6 months and older.

Directions for OTIPRIO dose preparation and handling are presented in Figure 1.The directions differ for each indication. Follow the correct directions.

Figure 1: Preparation and dosing directions for Acute Otitis Externa and for Otitis Media with Effusion.

figure 1

OTIPRIO may result in overgrowth of nonsusceptible bacteria and fungi. If such infections occur, institute alternative therapy.

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Otitis Media with Effusion

In two randomized, sham-controlled Phase 3 clinical trials, 530 pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement were treated with OTIPRIO or sham administered intratympanically as a single dose. The median age of the pediatric patients enrolled in the clinical trials was 1.5 years; 62% of patients were 6 months through 2 years of age and 38% of patients were greater than 2 years of age.

Adverse reactions that occurred in at least 3% of OTIPRIO patients and at an incidence greater than sham are presented in Table 1.

Acute Otitis Externa

In a single randomized, sham controlled Phase 3 clinical trial, 259 pediatric and adult patients with acute otitis externa were treated with OTIPRIO or sham administered by a healthcare professional to the external ear canal as a single dose (0.2 mL to each affected ear). The median age of the patients enrolled in the clinical trial was 34 years; 26% were pediatric patients (age 3 to 17 years), 65% were adults (age 18 to 64 years), and 8% were elderly patients (age 65 years and older).

Adverse reactions that occurred in at least 2% of OTIPRIO patients and at an incidence greater than sham are presented in Table 2.

Risk Summary

Animal reproduction studies have not been conducted with OTIPRIO. No adequate and well-controlled studies have been performed in pregnant women. Because of the negligible systemic exposure associated with clinical administration of OTIPRIO, this product is expected to be of minimal risk for maternal and fetal toxicity when administered to pregnant women.

Risk Summary

Ciprofloxacin is excreted in human milk with systemic administration. However, because of the negligible systemic exposure after otic application, nursing infants of mothers receiving OTIPRIO should not be affected.

The safety and effectiveness of OTIPRIO in infants below six months of age have not been established.

The safety and effectiveness of OTIPRIO was established in 530 pediatric patients with bilateral otitis media with middle ear effusion undergoing myringotomy with tympanostomy tube placement. The median age of patients enrolled in the clinical trials was 1.5 years; 62% of patients were 6 months through 2 years of age and 38% of patients were greater than 2 years of age [see Adverse Reactions (6.1) and Clinical Studies (14)].

The safety and effectiveness of OTIPRIO was established in 64 acute otitis externa pediatric patients that participated in the pivotal Phase 3 study. Efficacy observed in the pediatric patients in that study was no different from the older population. [see Adverse Reactions (6.1) and Clinical Studies (14)]

Clinical studies of OTIPRIO did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients [see Adverse Reactions (6.1) and Clinical Studies (14)].

Ciprofloxacin is a fluoroquinolone antibacterial [see Microbiology (12.4)].

The plasma concentration of ciprofloxacin following otic administration of OTIPRIO was not measured.

Mechanism of Action

The bactericidal action of ciprofloxacin results from interference with the enzyme DNA gyrase, which is needed for the synthesis of bacterial DNA.

Resistance

Bacterial resistance to fluoroquinolones can develop through chromosomally- or plasmid-mediated mechanisms. In vitro studies demonstrated cross-resistance between ciprofloxacin and some fluoroquinolones. There is generally no cross-resistance between ciprofloxacin and other classes of antibacterial agents, such as beta-lactams or aminoglycosides.

Antimicrobial Activity

Ciprofloxacin has been shown to be active against most isolates of the following bacteria:

Gram-positive Bacteria
    Staphylococcus aureus
    Streptococcus pneumoniae
Gram-negative Bacteria
    Haemophilus influenzae
    Moraxella catarrhalis
    Pseudomonas aeruginosa

Eight in vitro mutagenicity tests have been conducted with ciprofloxacin, and the test results are listed below:

      Salmonella/Microsome Test (Negative)
      Escherichia coli DNA Repair Assay (Negative)
      Mouse Lymphoma Cell Forward Mutation Assay (Positive)
      Chinese Hamster V79 Cell HGPRT Test (Negative)
      Syrian Hamster Embryo Cell Transformation Assay (Negative)
      Saccharomyces cerevisiae Point Mutation Assay (Negative)
      Saccharomyces cerevisiae Mitotic Crossover and Gene Conversion Assay (Negative)
      Rat Hepatocyte DNA Repair Assay (Positive)

Thus, 2 of the 8 in vitro tests were positive, but results of the following 3 in vivo test systems gave negative results:
      Rat Hepatocyte DNA Repair Assay
      Micronucleus Test (Mice)
      Dominant Lethal Test (Mice)

Long-term carcinogenicity studies in mice and rats have been completed for ciprofloxacin. After daily oral doses of 750 mg/kg in mice and 250 mg/kg in rats (for mice and rats respectively, approximately 300 and 200 times the maximum recommended clinical dose of ototopical ciprofloxacin based upon body surface area, assuming total absorption of ciprofloxacin from the ear of a patient treated with OTIPRIO) were administered for up to 2 years, there was no evidence that ciprofloxacin had any carcinogenic or tumorigenic effects in these species.

Fertility studies performed in rats at oral doses of ciprofloxacin up to 100 mg/kg/day revealed no evidence of impairment. This would be approximately 80 times the maximum recommended clinical dose of ototopical ciprofloxacin based upon body surface area, assuming total absorption of ciprofloxacin from the ear of a patient treated with OTIPRIO.

Guinea pigs dosed in the middle ear with OTIPRIO exhibited no drug-related structural or functional changes of the cochlear hair cells.

Two randomized, multicenter, sham-controlled clinical trials in 532 pediatric patients with bilateral otitis media with effusion undergoing myringotomy with tympanostomy tube placement evaluated the safety and efficacy of OTIPRIO when administered intratympanically as a single dose (NCT 01949155 and NCT 01949142). The median age of patients enrolled in the clinical trials was 1.5 years; 62% of patients were 6 months through 2 years of age and 38% of patients were greater than 2 years of age. The efficacy endpoint for both trials was the cumulative proportion of study treatment failures through Day 15, defined as the occurrence of any of the following events: otorrhea as determined by a blinded assessor on or after 3 days post-surgery, otic or systemic antibacterial drug use for any reason any time post-surgery, as well as patients who missed visits or were lost-to-follow-up. Table 3 presents the results from each Phase 3 trial.

Administration of OTIPRIO did not lead to impairment in hearing function, middle ear function or tube patency by Day 29.

One randomized multicenter, sham-controlled clinical trial in 262 pediatric and adult patients with unilateral or bilateral acute otitis externa was designed to evaluate the safety and efficacy of OTIPRIO when administered by a healthcare professional as a single dose to the external ear canal to patients aged 6 months and older (NCT 02801370). The median age of patients enrolled in the clinical trials was 34 years; 26% of patients were 3 to 17 years of age, 65% of patients were 18 to 64 years of age, and 8% of patients were greater than 65 years of age. No patients less than 3 years of age were enrolled.

The primary efficacy endpoint was the proportion of patients with clinical response at Day 8. Clinical response was defined as the complete absence of signs and symptoms of acute otitis externa (i.e., tenderness, erythema, edema, and otorrhea as determined by the blinded assessor), and no concomitant systemic or topical antibacterial drug (given in the study ear) was taken for any reason at or prior to the study visit. Table 4 contains the proportions of patients with clinical response at Day 8 in both the intent to treat (ITT) population which contains all subjects who were randomized and did not have group A streptococci cultured on Day 1 and the microbiological ITT population which contains all ITT subjects who had a positive culture for S. aureus or P. aeruginosa on Day 1.